RIGL - Rigel Pharmaceuticals, Inc.
| Previous Close | 2.5000 |
| Open | 2.5000 |
| Bid | 2.5000 x 4000 |
| Ask | 2.5100 x 1300 |
| Day's Range | 2.4800 - 2.5300 |
| 52 Week Range | 1.9600 - 3.6500 |
| Volume | 210,731 |
| Avg. Volume | 1,453,656 |
| Market Cap | 421.326M |
| Beta (3Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.•8 days ago
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Are Analysts Optimistic?
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL): Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the...
- Zacks•16 days ago
Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Rigel Pharmaceuticals, Inc. (RIGL) has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks•20 days ago
Dova Receives Approval for Doptelet in Europe, Stock Up
Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.
- Insider Monkey•23 days ago
Here’s What Hedge Funds Think About Rigel Pharmaceuticals, Inc. (RIGL)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- Motley Fool•last month
Is Rigel Pharmaceuticals a Buy?
The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?
- Thomson Reuters StreetEvents•last month
Edited Transcript of RIGL earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Rigel Pharmaceuticals Inc Earnings Call
- Zacks•2 months ago
Rigel Initiates Enrollment in Pivotal Blood Disorder Study
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
Motley Fool•2 months agoRigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript
RIGL earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 5.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Rigel: 1Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 11 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by ...
- Simply Wall St.•3 months ago
If You Had Bought Rigel Pharmaceuticals (NASDAQ:RIGL) Stock A Year Ago, You'd Be Sitting On A 40% Loss, Today
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders should be happy to see the share price up 16% in the last quarter. But that is minimal compensation for the share price under-performance over the last year. After all...
- Motley Fool•3 months ago
Here's Why Rigel Pharmaceuticals Gained 17.3% in March
The pharma company announced full-year 2018 operating results.
- Simply Wall St.•4 months ago
Is Rigel Pharmaceuticals, Inc.’s (NASDAQ:RIGL) CEO Overpaid Relative To Its Peers?
Raul Rodriguez has been the CEO of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies ofRead More...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of RIGL earnings conference call or presentation 28-Feb-19 10:00pm GMT
Q4 2018 Rigel Pharmaceuticals Inc Earnings Call
Motley Fool•5 months agoRigel Pharmaceuticals (RIGL) Q4 2018 Earnings Conference Call Transcript
RIGL earnings call for the period ending December 31, 2018.
- Benzinga•6 months ago
Rigel Rises On European Marketing Agreement For Autoimmune Drug
Small-cap biotech Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL )'s shares were advancing Wednesday after it announced an agreement to commercialize fostamatinib, its autoimmune disorder drug. What Happened ...
- Simply Wall St.•6 months ago
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): When Will It Breakeven?
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL): Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and Read More...
- Insider Monkey•7 months ago
Rigel Pharmaceuticals, Inc. (RIGL): Hedge Fund Sentiment Unchanged
Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]
- Benzinga•7 months ago
Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved
Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in ...
- Simply Wall St.•8 months ago
What does Rigel Pharmaceuticals Inc’s (NASDAQ:RIGL) Balance Sheet Tell Us About Its Future?
Rigel Pharmaceuticals Inc (NASDAQ:RIGL), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is RIGL Read More...
- Zacks•8 months ago
Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents•8 months ago
Edited Transcript of RIGL earnings conference call or presentation 6-Nov-18 10:00pm GMT
Q3 2018 Rigel Pharmaceuticals Inc Earnings Call
